OC0000459 reduces inflammation in the tissues in response to allergic stimuli in patients
with asthma. This clinical trial, in mildly asthmatic patients, studies the effects of
OC000459 and placebo on the asthmatic response to two known stimulants of the asthmatic
response in the lungs, namely cat hair, pollen or house dust mite and methacholine.
Phase:
Phase 2
Details
Lead Sponsor:
Oxagen Ltd
Collaborators:
King's College Hospital NHS Trust Medicines Evaluation Unit, Manchester, UK